Replies to post #19515 on Regen BioPharma Inc (RGBP)

[SidVicious]

And this is just now bothering you? Tommy boy has always had his hands in other ventures. He has to as REGEN is a joke of a company and could fold its tent at any time. Remember, Ichim sold medistem to XON for ~23 million dollars. Not sure how much he made from it but he obviously understands the fragile nature of a biotech company and also realized that any company run by David Koos isn't one that will ever make any money. It's not unlike these advisers that REGEN has hired. They all advise other start ups because its easy money. ICHIM is part of other companies for the same reason.

Btw, still no FDA IND approval and stock is moving in the direction of .10 cents instead of .20 cents still after all these months. All hype all the time with REGEN. Smoke and mirrors is what David Koos excels at.

[LaddyMan]

I don't see this as a new event or overly concerning, though it would be better if he was devoted to Regen in my opinion. This is his excerpt off of the REGEN website. It is clear that there is no ambiguity or confusion on Regen's part about the fact that T-Ich is really a gun for hire...it would seem. Even though he as been listed in many places as co-founding the company.

Thomas Ichim, PhD
Chief Scientific Officer and Board Member

Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. Dr. Ichim is a member of Vendevia Group, an innovative venture development organization focused on optimization of value in biotechnology ventures. He is scientific advisor to Orcrist Bio, Entest, and MBVaX. To date he has published 91 peer-reviewed articles and is co-editor of the textbook “RNA Interference: From Bench to Clinical Translation”. Ichim is an ad-hoc editor and sits on several editorial boards. Ichim is inventor on over 30 patents and patent applications.

Again, their objective as has been stated by the company is not to develop a full blown pharma company, so this type of structure may work out fine.

Regen is focused on identifying undervalued regenerative medicine applications in the stem cell/immunotherapy space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials.

They have stated in the past they want to license or similar (cant remember the wording) after P2 or so, and quit the heavy lifting at that point in time.

As long as there is not stealing of IP (not sure how this possible, and this is the part that bugs me a bit since T-Ich surely takes the info garnered at Regen to other entities, even if it is subconscious...((which it isn't ;-) )).

It is what it is. We SHOULD know very soon if the model may be viable. Sucks waiting, but I believe it will be worth it.

Got longer than intended. Not directed at you CV.

RGBP